C16 Globotriaosylceramide-d9 (d18:1/16:0-d9) (Synonyms: C16 Ceramide Trihexoside (d18:1/16:0-d9), Gb3 (d18:1/16:0-d9), N-Hexadecanoyl-d9 (13,13,14,14,15,15,16,16,16)-ceramide Trihexoside)

C16 Globotriaosylceramide-d₉ (d18:1/16:0-d₉) is intended for use as an internal standard for the quantification of C16 globotriaosylceramide by GC- or LC-MS. C16 Globotriaosylceramide (d18:1/16:0) is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide .¹ C16 Globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes.² It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder.³ Plasma levels of C16 globotriaosylceramide are increased in patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.⁴ [Matreya, LLC. Catalog No. 1551]

1.Lingwood, C.A., and Branch, D.R.The role of glycosphingolipids in HIV/AIDSDiscov. Med.11(59)303-313(2011) 2.Hoffmann, P., HÜlsewig, M., Duvar, S., et al.On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nanoelectrospray ionization tandem mass spectrometryRapid Commun. Mass. Spectrom.24(15)2295-2304(2010) 3.Feldt-Rasmussen, U., Rasmussen, A.K., Mersebach, H., et al.Fabry disease: A new challenge in endocrinology and metabolism•Eur. J. Endocrinol.146(6)741-742(2002) 4.Hou, Y., Li, J., Xie, H., et al.Differential plasma lipids profiling and lipid signatures as biomarkers in the early diagnosis of ovarian carcinoma using UPLC-MSMetabolomics12(18)(2015)